Applied StemCell, Inc.

Applied StemCell, Inc. Applied StemCell provides industry and academic researchers with the ability to leverage the power of induced pluripotent stem cells (iPSC) technology.

Headquartered in Milpitas, California. Applied StemCell Inc. (ASC) is a fast growing biotechnology company headquartered in Milpitas, California.

What would you cure with a 50 kb knock-in?We’ve successfully knocked in a 50 kilobase multifunctional DNA insert into hu...
11/11/2025

What would you cure with a 50 kb knock-in?

We’ve successfully knocked in a 50 kilobase multifunctional DNA insert into human induced pluripotent stem cells (iPSCs) using our proprietary TARGATT™ technology.

This milestone represents a significant advance in the size of DNA researchers can safely insert site-specifically into the human genome and get reliable expression from one or more expression cassettes. We’re excited to use this capability to empower cell therapy developers and accelerate the next generation of advanced therapies.

Our collaboration with Ansa Biotechnologies made this possible; their enzymatic DNA synthesis platform was used to construct the 50 kilobase fragment for this insertion. A huge thank you to the Ansa team for their support and innovation!

Read the full announcement: https://bit.ly/3LAAamI

What if you could simplify large DNA insertions into mammalian cells — with negligible off-target events?See it in actio...
11/06/2025

What if you could simplify large DNA insertions into mammalian cells — with negligible off-target events?

See it in action by trying a kit in your own lab.

Our TARGATT™ large knock-in technology lets you simplify site-specific, multi-protein insertions into the mammalian H11 safe harbor site — delivering efficient, reliable expression every time.

Whether you’re developing allogeneic cell therapies or engineering complex protein constructs, TARGATT™ technology helps you move faster, with precision built in. See the difference. Ask us about our kits:

• TARGATT™ iPSC Kits: https://bit.ly/47HZZZz
• TARGATT™ HEK293 Kits: https://bit.ly/4olpM0C
• TARGATT™ CHO Kits: https://bit.ly/4oYyRwl

If you’re attending ARM’s upcoming workshop on the Evolution of the CGT Sector, we hope you can join the panel discussio...
11/03/2025

If you’re attending ARM’s upcoming workshop on the Evolution of the CGT Sector, we hope you can join the panel discussion moderated by our Chief Scientific Officer, Ruby Tsai, Ph.D.

Unable to make it to Washington, DC? There’s a virtual option as well!

The panel “Scale-Up: Advancing allogeneic cell and gene therapy products” will take place on November 5, from 4:00 – 4:45 pm.

Register here: https://bit.ly/47AvVyS

Show off your costumes a day early in San Diego! 🎃🦇Our Senior Business Development Manager, Heather Lundie, will be at B...
10/29/2025

Show off your costumes a day early in San Diego! 🎃🦇

Our Senior Business Development Manager, Heather Lundie, will be at BVS’s Community Halloween Party & Vendor Expo tomorrow. Come show off your Halloween costume, enjoy complimentary food and drinks, and learn how our TARGATT™ large knock-in technology can accelerate your cell line development while ensuring safety and reliable expression. No random integrations, no tricks. Just treats.

Register now: https://bit.ly/48P9jwQ

We hate naked double-stranded DNA just as much as your cells do. 😠That’s why we provide the platform to keep your cells ...
10/29/2025

We hate naked double-stranded DNA just as much as your cells do. 😠

That’s why we provide the platform to keep your cells safe. TARGATT™ large knock-in technology has your DNA covered, ensuring no double-stranded breaks are left naked during genome engineering, eliminating off-target events.

Learn more about moving faster and safer with TARGATT™ technology: https://bit.ly/47vVCQW

Join our Chief Scientific Officer, Ruby Tsai, Ph.D., and learn how we can Unlock Allogeneic Cell Therapy.While autologou...
10/09/2025

Join our Chief Scientific Officer, Ruby Tsai, Ph.D., and learn how we can Unlock Allogeneic Cell Therapy.

While autologous cell therapies have provided new options for cancer patients, the approach is logistically complex, expensive, and not scalable.

Hear what Ruby Tsai, Ph.D., has to say about how allogeneic cell therapy developers are addressing this durability roadblock, as well as how genome engineering and induced pluripotent stem cells (iPSCs) are making scalable allogeneic cell therapies possible.

The webinar “Unlocking Allogeneic Cell Therapy: Exploring Durable Approaches” will take place on Wednesday, October 22, at 8 am PT / 11 am ET.

📌Save your spot: https://bit.ly/4q3ekbk

Cell and gene therapy developers have a gene knock-in problem.Cell and gene therapies require the insertion of large, co...
10/03/2025

Cell and gene therapy developers have a gene knock-in problem.

Cell and gene therapies require the insertion of large, complex DNA constructs into patient cells, but current tools cannot reliably deliver these constructs in a way that is:
• Safe – precise, site-specific, with no harmful off-target events

• Efficient – high integration rates for scalable manufacturing

• Predictable – consistent and reliable gene expression

Without a better knock-in solution, the full potential of cell and gene therapies cannot be realized.

At Applied StemCell, our mission is to empower scientists in the cell and gene therapy space to bring more life-saving therapies to market—which is why we offer TARGATT™ and S-SELeCT™ large knock-in technologies.

Connect with Dolores Baksh, Ph.D., Ruby Tsai, Ph.D., or Heather Lundie on LinkedIn or through the partnering portal to learn more at Meeting on the Mesa.

We’ll iPS-see you at the iPSC Drug Development Summit 👀James Lulo, Ph.D., and Kaytrina Anchelia will be at the iPSC Drug...
09/26/2025

We’ll iPS-see you at the iPSC Drug Development Summit 👀

James Lulo, Ph.D., and Kaytrina Anchelia will be at the iPSC Drug Development Summit in Boston on October 1-2, 2025, to discuss how our TARGATT™ Hypo hiPSC Knock-in Kit accelerates your iPSC-based cell therapy development.

Our hypoimmunogenic iPSC platform comes pre-built with TARGATT™ large knock-in technology, allowing you to quickly insert additional immune evasion and disease modifying genes at the H11 safe harbor locus so you can move faster.

Reach out to James Lulo, Ph.D., and Kaytrina on LinkedIn to find a time to meet, and let’s unleash the full power of biology together.

Let’s meet and eat at Ventura BioCenter!Join our Business Development team in Thousand Oaks at Biotech Vendor Services, ...
09/22/2025

Let’s meet and eat at Ventura BioCenter!

Join our Business Development team in Thousand Oaks at Biotech Vendor Services, Inc.'s Community Life Science Event on September 25, to talk about how our genome engineering platforms help you move faster and learn more in mammalian cells.

Our TARGATT™ large knock-in technology enables cell line development for protein expression and library construction directly in mammalian cells, opening the door to more biologically relevant studies that other genome engineering methods such as CRISPR, lentivirus, and transposons can’t deliver.

Meet with Heather Lundie in Thousand Oaks to get the conversation started.

See you there 🤝

We're thrilled to welcome Kaytrina Anchelia as a Director of Business Development. With nearly a decade of experience dr...
09/17/2025

We're thrilled to welcome Kaytrina Anchelia as a Director of Business Development. With nearly a decade of experience driving significant business growth at OmniaBio, iVexSol, and Akron Bio, she brings deep commercial expertise in the cell and gene therapy space.

Kaytrina will leverage her extensive experience to support developers in advancing their programs, forge strategic partnerships, and deliver exceptional value to our clients.

Her excitement and commitment to empowering our peers are exhilarating: “I believe the TARGATT™ genome engineering platform has the potential to solve some of the industry’s most pressing challenges, and I look forward to helping deliver that value to our partners.”

Please join us in welcoming Kaytrina in the comments below! 🎉 ⬇️

Let’s partner at Meeting on the Mesa 2025Our CEO Dolores Baksh, Ph.D., CSO Ruby Tsai, Ph.D., and VP of Sales and Marketi...
09/11/2025

Let’s partner at Meeting on the Mesa 2025

Our CEO Dolores Baksh, Ph.D., CSO Ruby Tsai, Ph.D., and VP of Sales and Marketing Michael Yurkovich, Ph.D. will be attending Meeting on the Mesa 2025.

We’d love to meet with you during the event to discuss how our TARGATT™ large knock-in technology accelerates and enables cell line development for therapeutic and screening applications.

We even offer kits with our hypoimmunogenic cell line that incorporates our pre-built TARGATT™ large knock-in technology, allowing you to move fast and insert additional immune evasion elements in a single reaction (up to 20kb, more with nested reactions).

We’re also looking for strategic collaborations in advancing in vivo therapies with S-SELeCT™—a genome engineering platform that ensures the safety of the next generation of cell and gene-based medicines and enables you to unleash the full power of biology.

There’s much to be discussed and limited slots to meet.

Schedule a time to meet now: https://bit.ly/461wH8D

We have your DNA covered—and your appetite too. Ask us about our kits at https://bit.ly/4lEOaYY's upcoming R&D Vendor Di...
08/22/2025

We have your DNA covered—and your appetite too.

Ask us about our kits at https://bit.ly/4lEOaYY's upcoming R&D Vendor Discovery Day in San Francisco on August 26 and learn about genome engineering without naked double-stranded breaks.

Enjoy complimentary food and drinks, and a raffle to win AirPods. See you there!

Register now for free: https://bit.ly/4fM7hio

Address

521 Cottonwood Drive Suite 111
Milpitas, CA
95035

Opening Hours

Monday 9am - 5pm
Tuesday 9am - 5pm
Wednesday 9am - 5pm
Thursday 9am - 5pm
Friday 9am - 5pm

Website

Alerts

Be the first to know and let us send you an email when Applied StemCell, Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Applied StemCell, Inc.:

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Our Story

Applied StemCell Inc. (ASC) is a fast growing biotechnology company headquartered in Milpitas, California. Our goal is to advance gene-editing and stem cell innovationfor biomedical research and the biotechnology industry. After years of research and development, ASC is proud to offer an optimized series of tools for basic research study, drug discovery, bio-processing, bio-production and preclinical applications.

We are currently focusing on three areas:

Cell line generation for bio-production and bioassays

Patient-relevant cell models for personalized medicine and